On the issue of cough treatment in COVID-19 patients
- Authors: Ovsyannikov E.S1, Feygelman S.N1, Alexeeva N.G1
-
Affiliations:
- Voronezh State Medical University named after N.N. Burdenko
- Issue: No 4S (2022): Supplement
- Pages: 99-102
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277102
- DOI: https://doi.org/10.18565/therapy.2022.4suppl.100-103
- ID: 277102
Cite item
Open Access
Access granted
Abstract
Unproductive cough is one of the most frequent complaints in COVID-19, therefore, levodropropizine, a peripheral antitussive agent, was prescribed to 98 patients for its treatment (basic group). The comparison group consisted of 29 patients with COVID-19 with the same complaints who voluntarily refused to take the specified drug. As a result of the study, it was found that during 7 days of treatment with levodropropizine, the intensity and severity of dry cough during the day and at night significantly decreased.
Full Text
About the authors
E. S Ovsyannikov
Voronezh State Medical University named after N.N. Burdenko
S. N Feygelman
Voronezh State Medical University named after N.N. Burdenko
N. G Alexeeva
Voronezh State Medical University named after N.N. Burdenko
References
- Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections - more than just the common cold. JAMA. 2020; 323(8): 707-8. doi: 10.1001/jama.2020.0757.
- Dicpinigaitis P.V., Morice A.H., Birring S.S. et al. Antitussive drugs - past, present, and future. Pharmacol Rev. 2014; 66(2): 468-512. doi: 10.1124/pr.111.005116.
- Государственный реестр лекарственных средств Минздрава России. Инструкция по применению лекарственного препарата с МНН леводропропизин. Доступ: https://grls.rosminzdrav.ru (дата обращения - 25.04.2022).
- Орлова Н.В. Хронический кашель: дифференциальная диагностика и лечение. Медицинский совет. 2020; 17: 124-131. doi: 10.21518/2079-701X-2020-17-124-131.
Supplementary files
